Histone demethylase PHF8 promotes prostate cancer metastasis via the E2F1SNAI1 axis

Author:

Wang Ze1,Tang Peng1,Xiao Haiyang1,Peng Song1,Chen Jian1,Wang Yapeng1,Xu Jing1,Yan Qian1,Zhang Junying23,Deng Jie1,Ma Qiang1,Zhu Hailin1,Luo Weiming1,Zhang Dianzheng4,Wang Luofu1,Qin Jun5,Lan Weihua1,Jiang Jun1ORCID,Liu Qiuli1ORCID

Affiliation:

1. Department of Urology, Daping Hospital Army Medical University Chongqing PR China

2. Chongqing Key Laboratory of High Active Traditional Chinese Drug Delivery System, Chongqing Engineering Research Center of Pharmaceutical Sciences Chongqing Medical and Pharmaceutical College Chongqing PR China

3. College of Pharmacy Chongqing Medical University Chongqing PR China

4. Department of Bio‐Medical Sciences Philadelphia College of Osteopathic Medicine Philadelphia PA USA

5. CAS Key Laboratory of Tissue Microenvironment and Tumor, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Nutrition and Health Sciences, Chinese Academy of Sciences University of Chinese Academy of Sciences Shanghai PR China

Abstract

AbstractMetastasis is the primary culprit behind cancer‐related fatalities in multiple cancer types, including prostate cancer. Despite great advances, the precise mechanisms underlying prostate cancer metastasis are far from complete. By using a transgenic mouse prostate cancer model (TRAMP) with and without Phf8 knockout, we have identified a crucial role of PHF8 in prostate cancer metastasis. By complexing with E2F1, PHF8 transcriptionally upregulates SNAI1 in a demethylation‐dependent manner. The upregulated SNAI1 subsequently enhances epithelial‐to‐mesenchymal transition (EMT) and metastasis. Given the role of the abnormally activated PHF8/E2F1‐SNAI1 axis in prostate cancer metastasis and poor prognosis, the levels of PHF8 or the activity of this axis could serve as biomarkers for prostate cancer metastasis. Moreover, targeting this axis could become a potential therapeutic strategy for prostate cancer treatment. © 2024 The Pathological Society of Great Britain and Ireland.

Funder

National Natural Science Foundation of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3